Please ensure Javascript is enabled for purposes of website accessibility

FDA Approves Eli Lilly's and Boehringer Ingelheim Pharmaceuticals' Triple-Combination Diabetes Drug Trijardy XR

By Brian Orelli, PhD - Updated Jan 28, 2020 at 9:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The combination treatment offers patients more convenience, but could also help the duo fight off competition.

On Monday, the Food and Drug Administration approved Trijardy XR, a combination treatment that contains three drugs already approved for type 2 diabetes: Jardiance, Tradjenta, and the generic drug metformin.

Eli Lilly (LLY 1.25%) and its partner, Germany-based Boehringer Ingelheim Pharmaceuticals, will market the drug, as they do Jardiance and Tradjenta. The companies formed a strategic alliance in 2011 that brought their diabetes pipelines together.

Boehringer Ingelheim arguably brought more to the deal -- it owned both Jardiance and Tradjenta -- while Eli Lilly initially made an upfront payment to its new ally to even out the alliance.

Doctor taking a blood glucose reading with medication on a table

Image source: Getty Images.

On the surface, Trijardy XR is simply designed for convenience since the healthcare companies aren't making any claims about how well the triple combination works. The FDA approval was based on two clinical trials that showed the single pill produced an equivalent effect to taking the three individual pills for healthy volunteers.

But both Jardiance, which is an SGLT2 inhibitor, and Tradjenta, which inhibits DPP-4, are in competitive drug classes -- multiple other treatments use the same mechanisms of action. Merck, for instance, sells SGLT2 inhibitor Steglatro and DPP-4 inhibitor Januvia. AstraZeneca markets SGLT2 inhibitor Farxiga and DPP-4 inhibitor Onglyza.

This triple-combination pill could help keep competition at bay and encourage diabetes patients to stay in the Eli Lilly/Boehringer Ingelheim family when their doctors want to add drugs in additional classes to their regimens. In fact, the companies already sell pills that pair each of the available double combinations -- Synjardy (Jardiance and metformin), Glyxambi (Jardiance and Tradjenta), and Jentadueto (Tradjenta and metformin) -- facilitating the progression from a single drug to two drugs, and eventually to Trijardy XR.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$302.60 (1.25%) $3.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.